miR-1297 sensitizes glioma cells to temozolomide treatment by targeting adrenomedullin. The Bax/Bcl-2, Akt, and Erk1/2 signaling pathways, as well as mitochondrial functions, might be involved
1)
He Z, Cheng M, Hu J, Liu L, Liu P, Chen L, Cao D, Tang J. miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM). J Transl Med. 2022 Oct 1;20(1):443. doi: 10.1186/s12967-022-03647-6. PMID: 36183123.